Publications by authors named "Mu-chen Zhang"

Claim this Profile
B
Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Yue Wang, Qing Shi, Zi-Yang Shi, Shuang Tian, Mu-Chen Zhang

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.
Mu-Chen Zhang, Shuang Tian, Di Fu, Li Wang, Shu Cheng

Cancer Cell· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma.
Ying Fang, Mu-Chen Zhang, Yang He, Chen Li, Hai Fang

Signal Transduct Target Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Rong Shen, Di Fu, Lei Dong, Mu-Chen Zhang, Qing Shi

Signal Transduct Target Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genome-wide chromatin accessibility and transcriptome profiling of diffuse large B-cell lymphoma.
Ying Fang, Mu-Chen Zhang, Peng-Peng Xu, Su-Jiang Zhang, Li Wang

Clin Transl Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.
Yu-Jia Huo, Peng-Peng Xu, Li Wang, Hui-Juan Zhong, Di Fu, Mu-Chen Zhang

Biomark Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.
Mu-Chen Zhang, Ying Fang, Peng-Peng Xu, Lei Dong, Rong Shen

Clin Transl Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin's lymphoma and their role in predicting patient survival.
Yan Wang, Zhao-Cheng Pan, Lan Zhu, Yuan-Yuan Ma, Mu-Chen Zhang

Quant Imaging Med Surg· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Mu-Chen Zhang, Ying Fang, Li Wang, Shu Cheng, Di Fu

Clin Epigenetics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Zi-Xun Yan, Li Li, Wen Wang, Bin-Shen OuYang, Shu Cheng, Mu-Chen Zhang

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases.
Mu-Chen Zhang, Min Zhou, Qi Song, Shuo Wang, Qing Shi

Lung Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)].
Ye Xu, Jia-ying Zhang, Bo-yu Yang, Zhi-hong He, Mu-chen Zhang

Yi Chuan· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis